{
    "root": "564261a6-c6b6-4d31-bf80-36fe086e73e8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Mercaptopurine",
    "value": "20241001",
    "ingredients": [
        {
            "name": "MERCAPTOPURINE",
            "code": "E7WED276I5"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, POTATO",
            "code": "8I089SAH3T"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "STEARIC ACID",
            "code": "4ELV7Z65AP"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "mercaptopurine tablets nucleoside metabolic inhibitor indicated treatment adult pediatric patients acute lymphoblastic leukemia ( ) part combination chemotherapy maintenance regimen . ( 1.1 )",
    "contraindications": "• recommended starting dose mercaptopurine tablets 1.5 mg/kg 2.5 mg/kg orally daily part combination chemotherapy maintenance regimen . adjust dose maintain desirable absolute neutrophil count excessive myelosuppression . ( 2.1 ) • renal impairment : lowest recommended starting dose increase dosing interval . ( 2.3 , 8.6 ) • hepatic impairment : lowest recommended starting dose . ( 2.3 , 8.7 )",
    "warningsAndPrecautions": "mercaptopurine tablets , usp 50 mg supplied pale yellow , biconvex tablets , product identification “ 54 420 ” one side score side . ndc 0054-4581-11 : bottle 25 tablets ndc 0054-4581-27 : bottle 250 tablets store 20°c 25°c ( 68°f 77°f ) . [ usp controlled room temperature . ] store dry place . dispense tight , child-resistant container defined usp/nf . mercaptopurine tablets cytotoxic . follow special handling disposal procedures1 .",
    "adverseReactions": "none .",
    "indications_original": "Mercaptopurine Tablets is a nucleoside metabolic inhibitor indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. (1.1)",
    "contraindications_original": "• The recommended starting dose of Mercaptopurine Tablets is 1.5 mg/kg to 2.5 mg/kg orally once daily as part of a combination chemotherapy maintenance regimen. Adjust dose to maintain desirable absolute neutrophil count and for excessive myelosuppression. (2.1) • Renal Impairment: Use the lowest recommended starting dose or increase the dosing interval. (2.3, 8.6) • Hepatic Impairment: Use the lowest recommended starting dose. (2.3, 8.7)",
    "warningsAndPrecautions_original": "Mercaptopurine Tablets, USP\n                  \n                  \n                     50 mg supplied as pale yellow, biconvex tablets, with product identification “54 420” on one side and a score on the other side. \n                  \n                  NDC 0054-4581-11: Bottle of 25 Tablets\n                  NDC 0054-4581-27: Bottle of 250 Tablets \n                  Store at 20°C to 25°C (68°F to 77°F). [See USP Controlled Room Temperature.] Store in a dry place. Dispense in a tight, child-resistant container as defined in the USP/NF.\n                  Mercaptopurine Tablets is a cytotoxic drug. Follow special handling and disposal procedures1.",
    "adverseReactions_original": "None."
}